Tiedemann Advisors’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Tiedemann Advisors’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-17,243	Closed	-$148K	–	376
2021 Q2	$148K	Hold	17,243	–	–	0.01%	352
2021 Q1	$188K	Hold	17,243	–	–	0.01%	320
2020 Q4	$170K	Sell	17,243 -73,536	-81%	-$481K	0.01%	307
2020 Q3	$486K	Hold	90,779	–	–	0.02%	230
2020 Q2	$533K	Hold	90,779	–	–	0.03%	208
2020 Q1	$338K	Sell	90,779 -15,493	-15%	-$80.2K	0.02%	227
2019 Q4	$672K	Sell	106,272 -3,125	-3%	-$39.7K	0.03%	193
2019 Q3	$1.5M	Buy	109,397 +6,385	+6%	+$105K	0.07%	140
2019 Q2	$1.52M	Hold	103,012	–	–	0.08%	126
2019 Q1	$4.32M	Hold	103,012	–	–	0.2%	82
2018 Q4	$4.28M	Hold	103,012	–	–	0.22%	79
2018 Q3	$4.96M	Hold	103,012	–	–	0.29%	63
2018 Q2	$4.88M	Hold	103,012	–	–	0.31%	65
2018 Q1	$6.34M	Hold	103,012	–	–	0.43%	47
2017 Q4	$5.54M	Buy	+103,012	New	+$6.13M	0.42%	47
2017 Q3	–	Sell	-90,512	Closed	-$4.9M	–	466
2017 Q2	$4.9M	Buy	90,512 +12,889	+17%	+$597K	0.36%	50
2017 Q1	$2.76M	Buy	+77,623	New	+$2.66M	0.23%	91

Other funds holding FSTX

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tiedemann Advisors's FSTX Position: Q3 2021 in Review

Tiedemann Advisors sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2021, closing a stake of 17,243 shares — an estimated $148K sold.

Tiedemann Advisors first reported a position in FSTX in Q1 2017 and held it in 17 quarters. The position peaked at $6.34M in Q1 2018. 37 funds tracked by Wall St. Rank hold FSTX as of Q3 2021.

Tiedemann Advisors reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Tiedemann Advisors sold 17,243 F-star Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $148K.
Tiedemann Advisors first reported a position in F-star Therapeutics, Inc. Common Stock in Q1 2017 and held it in 17 quarters.
Tiedemann Advisors's F-star Therapeutics, Inc. Common Stock position peaked at $6.34M in Q1 2018.
37 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Tiedemann Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.